Basic Information
| LncRNA/CircRNA Name | CASC2 |
| Synonyms | CASC2, C10orf5 |
| Region | GRCh38_10:118046279-118210153 |
| Ensemble | ENSG00000177640 |
| Refseq | NR_026939 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot etc. |
| Sample | HCC tissues, cell lines (MHCC-97L, Hep-3B, HepG2, Huh7, SMMC-7721, MHCC-97H and LO2) |
| Expression Pattern | down-regulated |
| Function Description | CASC2 expression was markedly downregulated in aggressive HCC tissues compared with non-aggressive HCCs (P < 0.01, Fig.1b). The CASC2/miR-367/FBXW7 axis may be a ponderable and promising therapeutic target for HCC. CASC2 low-expressing and miR-367 high-expressing HCC patients showed the poorest clinical outcome. CASC2 was recognized as a competing endogenous RNA (ceRNA) for miR-367 and could exert its anti-metastatic effects on cell migration, invasion and EMT progression through CASC2/miR-367/FBXW7 axis, which might inject some new vitalities into the development therapeutic targets for HCC. |
| Pubmed ID | 28716020 |
| Year | 2017 |
| Title | Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. |
External Links
| Links for CASC2 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |